SynthesisArchives of disease in childhood2006
Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.
Synthesis in Archives of disease in childhood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Bisphosphonate therapy for osteogenesis imperfecta.The Cochrane database of systematic reviews · 2016Pooled it
- Skeletal health of children and adolescents with inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2011Guideline
- Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis.Inflammopharmacology · 2026Article
- Bone Health in Children with Rheumatic Disorders: Focus on Molecular Mechanisms, Diagnosis, and Management.International journal of molecular sciences · 2022Review
- Clinical practice guidelines for optimizing bone health in Korean children and adolescents.Annals of pediatric endocrinology & metabolism · 2022Article
- Growth and puberty in children with juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2021Review
- Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children.Pediatric rheumatology online journal · 2020Article
- Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.Paediatric drugs · 2017Review
- Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids.Pediatric rheumatology online journal · 2016Article
- Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.Current osteoporosis reports · 2014Review
- Causes, mechanisms and management of paediatric osteoporosis.Nature reviews. Rheumatology · 2013Review
- Nephrotoxicity as a cause of acute kidney injury in children.Pediatric nephrology (Berlin, Germany) · 2008Review
- Chronic pediatric inflammatory diseases: effects on bone.Reviews in endocrine & metabolic disorders · 2008Review
- Osteoporosis in juvenile idiopathic arthritis--a practical approach to diagnosis and therapy.European journal of pediatrics · 2007Review
- Can bisphosphonate treatment be stopped in a growing child with skeletal fragility?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the currently available evidence for the effectiveness of bisphosphonates in children with low bone mineral density (BMD) and fragility fractures associated with juvenile idiopathic arthritis (JIA), and the safety of bisphosphonates in JIA and other conditions.
methodsLiterature databases were searched using a structured search strategy. The effectiveness review included any studies of children with JIA treated with bisphosphonates. The safety review also included studies of osteogenesis imperfecta. Quantitative data analysis was not undertaken because of the heterogeneity of the studies; findings were summarised using tables and narrative synthesis.
resultsNinety four studies were identified. Sixteen studies (78 JIA children) were included in the effectiveness review: one randomised controlled trial, three controlled cohort studies, 11 case series, and one case report. At baseline, children had low BMD below the expected values for age and sex matched children. In all studies, treatment with bisphosphonates increased BMD compared with baseline: the mean percentage increase in spine BMD ranged from 4.5% to 19.1%. Overall, studies were heterogeneous and of variable quality. A total of 59 papers were included in the safety review; treatment durations were up to three years. The most common side effect was a flu-like reaction with intravenous treatment. This occurred during the first infusion and was transient; the symptoms were managed with paracetamol and did not occur during subsequent cycles.
conclusionsBisphosphonates are a promising treatment for low BMD and fragility fractures in children with JIA. However, the quality of the current evidence is variable and better studies are needed to more clearly assess their role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.